Armed with $90-million investment from the parent, pharma multinational AstraZeneca will be launching newer drugs across three therapeutic areas — cardiovascular, diabetes and respiratory for the Indian market.
Gagandeep Singh Bedi, MD, AstraZeneca India Pharma, told BusinessLine that the new investment will support scientific data generation to improve the standard of care of non-communicable diseases (NCDs) in India. The investment will be spread over a period of five years. He said some of the drugs introduced in the country are now able to prolong patients’ lives twice the number of months than before.
Focus on NCDs
He said AstraZeneca believes that ‘data’ will be one of the most important aspects in therapeutics and has identified areas in digital therapeutics that will contribute to better healthcare in NCDs. More initiatives are in the pipeline to ensure that AstraZeneca will continue to be one of the most effective contributors in the management of NCDs in India and the world.
Bu hikaye The Hindu Business Line dergisinin September 27, 2019 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye The Hindu Business Line dergisinin September 27, 2019 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Covid Presents An Opportunity For India
India must attract investors exiting China post-Covid. Streamlining of project clearances and relaxation in FRBM norms will help
Did Alternative Assets Shield You From Covid-19 Volatility?
The assets closely linked to stock and debt markets could not stave off the losses
How To Put Aircraft To Bed
Preserving grounded planes, to get them up and flying at short notice, is a challenging task. Ashwini Phadnis captures the process
There Can Be No Going Back On WFH
Covid-19 has fast-forwarded the shift to ‘work from home’. However, some face-to-face connect will always be needed
UN, WHO Urged To Ensure ‘Benefit Sharing' Of Covid-Related Data
Biopharma firms should reach vaccines, medicines to poor nations at an affordable price, say civil society bodies
With No Clear Signal From Rlys, States Explore Ways To Bring Back Migrants
Quarantine centres, cross-country buses being arranged even as migrants hop on to boats, trucks and ambulances
Centre Allows All Neighbourhood Shops To Open But With Riders
Final call will be taken by local authorities; shopping complexes that draw fewer ‘outsiders’ are permitted to operate
Covid Impact Relatively Muted In India
Compared to Italy and the US, India’s rate of infection spread has been slow. This can be attributed to the strict measures in place
How Global Trade Will Fare Post-Covid
China isn’t likely to lose its pre-eminent position soon. India, for one, will need to make manufacturing globally competitive
How To Curb Harassment In The Virtual Office
Training and sensitisation are essential. Institute a strict dress code and chat etiquette to ensure professionalism during video calls
